Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31. https://doi.org/10.1056/NEJMoa1607751.

Article  CAS  PubMed  Google Scholar 

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–66. https://doi.org/10.1056/NEJMoa1606038.

Article  CAS  PubMed  Google Scholar 

Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–97. https://doi.org/10.1016/s0140-6736(20)30734-0.

Article  CAS  PubMed  Google Scholar 

Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–28. https://doi.org/10.1056/NEJMoa1714678.

Article  CAS  PubMed  Google Scholar 

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29–38. https://doi.org/10.1016/s0140-6736(19)31240-1.

Article  CAS  PubMed  Google Scholar 

Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–15. https://doi.org/10.1056/NEJMoa1817249.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakagawa R, Onishi Y, Kawajiri A, Onodera K, Furukawa E, Sano S, et al. Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma. Ann Hematol. 2019;98(8):1999–2001. https://doi.org/10.1007/s00277-019-03645-7.

Article  PubMed  Google Scholar 

Tabata R, Sato N, Yamauchi N, Guo YM, Nakamura H, Nagata A, et al. Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens. Ann Hematol. 2022;101(2):465–7. https://doi.org/10.1007/s00277-021-04525-9.

Article  PubMed  Google Scholar 

Li S, Zheng G, He J, Wu W, Chen Q, Yang Y, et al. Cytomegalovirus and Epstein–Barr virus infection during daratumumab treatment in patients with multiple myeloma. Leuk Lymphoma. 2023;64(4):835–45. https://doi.org/10.1080/10428194.2023.2172982.

Article  CAS  PubMed  Google Scholar 

Frerichs KA, Bosman PWC, Nijhof IS, Zweegman S, van de Donk N. Cytomegalovirus reactivation in a patient with extensively pretreated multiple myeloma during daratumumab treatment. Clin Lymphoma Myeloma Leuk. 2019;19(1):e9–11. https://doi.org/10.1016/j.clml.2018.10.002.

Article  PubMed  Google Scholar 

Lavi N, Okasha D, Sabo E, Oren I, Benyamini N, Bar-Yoseph H. Severe cytomegalovirus enterocolitis developing following daratumumab exposure in three patients with multiple myeloma. Eur J Haematol. 2018. https://doi.org/10.1111/ejh.13164.

Article  PubMed  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8. https://doi.org/10.1038/bmt.2012.244.

Article  CAS  PubMed  Google Scholar 

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–44. https://doi.org/10.1056/NEJMoa1706640.

Article  CAS  PubMed  Google Scholar 

Zhang T, Scott JM, Hwang I, Kim S. Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRgamma deficiency. J Immunol. 2013;190:1402–6.

Article  CAS  PubMed  Google Scholar 

Ge AY, Huang CY, Banerjee R, Knoche J, Chung A, Arora S, et al. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: a single-centre retrospective study. Br J Haematol. 2023;201:935–9.

Article  CAS  PubMed  Google Scholar